Results 181 to 190 of about 28,141,875 (293)

Healthy eating among people with type 2 diabetes in the Brazilian Amazon: a qualitative study in primary health care. [PDF]

Cad Saude Publica
Farias TADS, Ueno TMRL, Monteiro WF, Campos HLM, Leon EB.   +4 more
europepmc   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Disorganized bone collagen fibers in early-stage type 2 diabetes mellitus and its association with adipose tissue redistribution. [PDF]

Eur Radiol Exp
Liu Y, Meng Q, Chen S, Zhang X, Gao L, Wang M, Bai L, Zhang X, Zhang P, Zheng N, Zhao J.   +10 more
europepmc   +1 more source

Impact of the pancreatic enzyme replacement therapy (PERT) shortage on prescribing in England: Analysis of national data

British Journal of Clinical Pharmacology, EarlyView.
Aim Pancreatic enzyme replacement therapy (PERT) is essential for the management of pancreatic exocrine insufficiency. Since June 2023, the United Kingdom has been affected by a global shortage of PERT. We investigated the impact of this shortage on national prescribing trends for Creon, Nutrizym, Pancrex and Pangrol.
Teena S. Varghese, Mary E. Phillips, Louis Fisher, Helen Fitt, Adam Frampton, Christopher Wood, Agnieszka Lemanska   +6 more
wiley   +1 more source

Health-related quality of life among patients with type 2 diabetes mellitus using EuroQol five-dimension five level: A cross-sectional study from an urban health training center, Coimbatore, India. [PDF]

J Educ Health Promot
Soundararajan S, Kumar RS, Veronika M, Shankar SLR, Nanjundan R.   +4 more
europepmc   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

Central Auditory Pathway Dysfunction in Type 2 Diabetes Mellitus: A Narrative Review of Auditory Brainstem Response Alterations. [PDF]

Cureus
Abbass A, Waheed S, Kaur V, Bobbara A, Anand A.   +4 more
europepmc   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Associations of dietary fiber knowledge and intake with glycemic control among Jordanian patients with type two diabetes mellitus: a cross-sectional study. [PDF]

Food Nutr Res
Hamed DA, Alkurd RA, Abujbara M, Khader Y, Ajlouni KM.   +4 more
europepmc   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source